GlassScriptPhysician profile
Sashank Kolli
NPI 1205140985
$4,355.64
in general payments reported to CMS, 2019-2025
22 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $91.41 · 2021: $465 · 2022: $634 · 2023: $913 · 2024: $848 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.22 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,303.65 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $885.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $280.44 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $265.95 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.40 | 2019-2023 | Stiolto Respimat |
| Philips North America LLC | $189.22 | 2021-2022 | |
| Genzyme Corporation | $180.81 | 2023-2025 | |
| Mylan Specialty L.P. | $171.31 | 2022-2024 | Yupelri |
| Pulmonx Corporation | $158.06 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Amgen INC. | $135.42 | 2022-2025 | Tezspire, Uplizna |
| Abiomed | $104.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.35 | 2024-2025 | Glassia |
| Pfizer INC. | $65.80 | 2020-2025 | |
| Intuitive Surgical, INC. | $55.85 | 2024 | |
| Viatris Specialty LLC | $51.30 | 2025 | Yupelri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $50.44 | 2023-2024 | Acthar |
| United Therapeutics Corporation | $43.70 | 2023-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $43.47 | 2023 | Xarelto |
| Genentech USA, INC. | $38.00 | 2019 | |
| Insmed, INC. | $36.96 | 2025 | Brinsupri |
| Verona Pharma, INC. | $16.60 | 2025 | Ohtuvayre |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sashank Kolli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.